Sign in
4

Changes in Ownership

Edgewise Therapeutics, Inc. Filed Acc 0001562180-25-001025

President and CEO sold 9,536 shares at an average $30.13 ($287,316)

  • President and CEO acquired 9,536 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Insider Date Transaction Shares Price Value Owned after D/I In the form
KOCH KEVIN President and CEO 2025-02-05 Option exercise 10b5-1 +8,636 $0.18 $1,554 23,114 D
KOCH KEVIN President and CEO 2025-02-05 Sale 10b5-1 −8,636 $30.03 $259,298 14,478 D
KOCH KEVIN President and CEO 2025-02-06 Option exercise 10b5-1 +900 $13.11 $11,799 15,378 D
KOCH KEVIN President and CEO 2025-02-06 Sale 10b5-1 −900 $31.13 $28,018 14,478 D
Derivatives
KOCH KEVIN President and CEO 2025-02-05 Option exercise · Stock Option (Right to Buy) 10b5-1 −8,636 42,545 D
KOCH KEVIN President and CEO 2025-02-06 Option exercise · Stock Option (Right to Buy) 10b5-1 −900 41,645 D
Open-market sales · 9,536 sh · avg $30.13 · $287,316
Loading xslF345X05/primarydocument.xml…